anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an external Chinese medicinal composition for treating chronic nephropathy, which belongs to the field of Chinese medicaments (external products). The external Chinese medicinal composition comprises: pepper, dragon blood, clematis root, common burreed rhizome, motherwort herb, cape jasmine fruit and artificial musk. The method for preparing the external Chinese medicinal composition comprises the following steps: pulverizing the seven medicaments into fine powder; and putting the fine powder into 12*18cm of woolen cloth bag for standby, and the weight of per bag is 125g. Before being used, the Chinese medicinal composition is fully soaked with vinegar; and after the soaked Chinese medicinal composition is heated appropriately, the heated Chinese medicinal composition is externally applied to shen shu acupuncture points of both sides. The external Chinese medicinal composition has functions of warming meridians to move water, promoting blood to dispel stasis, dispelling wind and freeing the collateral vessels, detoxicating and resolving a mass and dispelling the rotten and promoting tissue regeneration. The observation of clinical efficacy confirms that the external Chinese medicinal composition has the obvious curative effect on the chronic nephropathy, and is suitable for the chronic nephropathy caused by various reasons.
The present disclosure, among other things, provides a composition of a particle including a substrate; at least a first condensation layer comprising at least a first dopant entity; and at least a second layer comprising a second dopant entity. In some embodiments, different dopant entities are included in different layers. In some embodiments, such dopant entities are or comprise detectable entities. This, in some embodiments, provided technologies achieve multi-modality particles. Among the many advantages of provided technologies include the ability to image particles by a plurality of distinct imaging modalities and/or in a plurality of contexts (e.g., pre-surgical, intraoperative and/or post-surgical environments). The present invention provides methods that include a single administration of particles to a subject, followed by a plurality of steps that comprise imaging the administered particles, which steps may utilize different imaging technologies and/or be performed at different times and/or in different environments.
The current COVID-19 mRNA vaccines were developed and applied for pandemic-emergent conditions. These vaccines use a small piece of the virus's genetic material (mRNA) to stimulate an immune response against COVID-19. However, their potential effects on individuals with chronic inflammatory conditions and vaccination routes remain questionable. Therefore, we investigated the effects of mRNA vaccines in a mouse model of chronic inflammation, focusing on their cardiac toxicity and immunogenicity dependent on the injection route. mRNA vaccine intravenous administration with or without chronic inflammation exacerbated cardiac pericarditis and myocarditis; immunization induced mild inflammation and inflammatory cytokine IL-1beta and IL-6 production in the heart. Further, IV mRNA vaccination induced cardiac damage in LPS chronic inflammation, particularly serum troponin I (TnI), which dramatically increased. IV vaccine administration may induce more cardiotoxicity in chronic inflammation. These findings highlight the need for further research to understand the underlying mechanisms of mRNA vaccines with chronic inflammatory conditions dependent on injection routes.
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome caused by liver insufficiency and/or portosystemic shunting. HE is mostly episodic and as such reversible. Hyperammonemia clearly plays a key role in the pathophysiology, but the precise detrimental events in the brain leading to HE remain equivocal. Several pathogenic models have been proposed, but few have been linked to clinical studies and observations. Decreased oxygen metabolism is observed in both type A and C HE and in this review, we advocate that this reflects an actual reduced oxygen demand and not a primary cause of HE. As driving force, we propose that the hyperammonemia via astrocytic glutamine synthetase causes an increased γ-aminobutyric acid (GABA) mediated neuro-inhibition which subsequently leads to an overall decreased energy demand of the brain, something that can be enhanced by concomitant neuroinflammation. This also explains the reversibility of the condition.
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
The present invention relates to a deoxycholic acid (DOCA) composition with an improved lipolysis effect and a method for preparing the same. In the composition of the present invention, amino acid, which is a hydrophilic part, is added to DOCA, so that like a surfactant, both a hydrophilic part and a hydrophobic part are present in the composition. As such, a solubilization ability of a fat-soluble component (fat) can be further increased, and the composition's solubility in water can be increased by increasing the hydrophilicity to DOCA. Accordingly, the composition is easy to prepare as an injection when the solubility of DOCA is increased. After injection, there is no precipitate under biological pH conditions, and thus, inflammatory reactions and the like can be minimized. Therefore, the composition can be applied as an injection for lipolysis.
The traditional Chinese medicine treatment group received modified Jiedu Yizhi Formula therapy, with no more than 3 flavors, customized based on syndrome differentiation. The herbal composition included 10g of Coptis chinensis Franch (Huanglian, Ranunculaceae, rhizome), 20g of Alpinia oxyphylla Miq.(Yizhiren, Zingiberaceae, fructus), 10g of Chinemys reevesii(Guibanjiao), 10g of Rheum webbianum (Jiu Dahuang, rhizome), 10g of Cornus officinalis (Shanzhuyu, Cornaceae, fructus), 10g of Pheretima aspergillum (Dilong), and 10g of Oreocome striata (Chuanxiong, Apiaceae, rhizome). 300ml of water decoction juice was prepared from each pair of herbs, and 100ml was taken daily after breakfast and dinner.
PURPOSE:To obtain the titled gelatin substrate for drug preparation giving an encapsulation film having suppressed hardening phenomenon and delay of disintegration time, by adding a specific amount of cyclodextrin to gelatin. CONSTITUTION:A gelatin substrate produced by adding 10-2wt% cyclodextrin to gelatin. Although various drug preparations prepared by using a gelatin substrate have excellent advantages, they are inferior in stability and disintegrability, etc. Cyclodextrin is a malto-oligosaccharide wherein glucose molecules are linked with each other with alpha-1,4-glycoside bond in the form of a ring. It is composed mainly of 6-8 glucose units corresponding to cyclohexa-, cyclohepta- and cycloocta-dextrin each of which has alpha-, beta- and gamma-isomers. The problems of hardening phenomenon and delay of disintegration time have been solved by the addition of cyclodextrin to gelatin.
The present invention concerns medicine, and describes a novel application of PRS in the treatment of autonomic dysregulations of the vagal dysfunction type, and more specifically symptomatic dysautonomic tachycardia following severe vagal dysfunction. PRS is a drug belonging to the anticholinesterase family. This molecule is also indicated in the presence of a vagal dysfunction found in HTN. The invention provides a novel pharmacological means for treating autonomic dysregulations of the vagal dysfunction type, with a beneficial effect of PRS. The novel application of the drug has an action with a dose of 60 to 120 mg taken orally twice daily, thus increasing vagal activity. Vagal dysfunction is diagnosed by vagal stimulation tests. The novel application has a positive effect on the vagus nerve, thus helping reduce AP (arterial pressure) and HR when the latter are abnormally high or when vagal stimulation tests show a weak response.
Antioxidant-rich diets serve as protective factors in preventing obesity. The composite dietary antioxidant index (CDAI) represents a novel, comprehensive metric for assessing the antioxidant capacity of diets. Our objective is to investigate the relationship between the CDAI and obesity prevalence among adults in the United States. Dietary and anthropometric information about adults aged 20 years and older were obtained from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. The CDAI was derived from six dietary antioxidants. Obesity is defined as a body mass index (BMI, kg/m2) ≥ 30 kg/m2, and abdominal obesity as a waist circumference (WC, cm) ≥ 102 cm for men and ≥ 88 cm for women. The relationship between CDAI and obesity, including abdominal obesity, was analyzed using logistic regression and subgroup analyses. A total of 25,553 participants were analyzed. With higher tertiles of the CDAI, both obesity (41.28% vs. 38.62 vs. 35.09%, P < 0.001) and abdominal obesity (63.75% vs. 59.54 vs. 52.09%, P < 0.001) prevalence notably declined. Adjusting for multiple confounders, the CDAI was found to be independently linked to obesity (OR = 0.980, 95%CI = 0.971-0.989, P < 0.001) and abdominal obesity (OR = 0.972, 95%CI = 0.963-0.982, P < 0.001) risks. Subgroup analyses revealed a stronger relationship between CDAI and obesity in non-hypertensive individuals and a more significant association with abdominal obesity in women and those without hypertension. Our findings reveal a negative relationship between CDAI levels and both general and abdominal obesity. Additional extensive research is necessary to investigate CDAI's contribution to obesity.
Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
Strategic test allocation is important for control of both emerging and existing pandemics (eg, COVID-19, HIV). It supports effective epidemic control by (1) reducing transmission via identifying cases and (2) tracking outbreak dynamics to inform targeted interventions. However, infectious disease surveillance presents unique statistical challenges. For instance, the true outcome of interest (positive infection status) is often a latent variable. In addition, presence of both network and temporal dependence reduces data to a single observation. In this work, we study an adaptive sequential design, which allows for unspecified dependence among individuals and across time. Our causal parameter is the mean latent outcome we would have obtained, if, starting at time t given the observed past, we had carried out a stochastic intervention that maximizes the outcome under a resource constraint. The key strength of the method is that we do not have to model network and time dependence: a short-term performance Online Super Learner is used to select among dependence models and randomization schemes. The proposed strategy learns the optimal choice of testing over time while adapting to the current state of the outbreak and learning across samples, through time, or both. We demonstrate the superior performance of the proposed strategy in an agent-based simulation modeling a residential university environment during the COVID-19 pandemic.
Post-treatment cancer survivorship is often associated with a void in care given the drop-off in support provided to survivors from the medical team as well as family and friends. In addition, cancer associated symptoms and impaired quality of life remain significant problems for patients despite advances in cancer treatment. Few effective treatment options exist for these symptoms. Integrative medicine is rising in popularity in the United States; however, few integrative medicine modalities have been rigorously studied. Ayurveda, a whole system of medicine that originated in the Indian subcontinent, has its own system of diagnostics and therapeutics, and among its strengths are wellness and prevention. In the Integrative Medicine intervention, Ayurvedic nutrition and lifestyle guidance will be presented, along with instruction in Yoga. In the Health Education intervention, informative content on issues relevant to breast cancer survivors will be presented including the physical, social and emotional impacts of survivorship. The investigators aim to perform a pilot RCT in breast cancer survivors with impaired quality of life. Specifically, the investigators aim to assess feasibility of randomization, adherence and retention to the Integrative Medicine and Health Education interventions.
PURPOSE:To provide the subject new compound useful for preventing and improving dysuria such as pollakiuria or incontinence of urine. CONSTITUTION:A compound of formula I (R<1> and R<2> are each H or a lower aliphatic hydrocarbon which may be substituted; R<3> is H or an aryl which may be substituted; R<4> is an aryl which may be substituted), e.g. hydrochloride of N-tert-butyl-2,3-diphenyl-2-cyclopentene-1-amine. The compound of formula I can be obtained by reacting a compound of formula II (X is an eliminable group) with a compound of formula III preferably in the presence of a base (e.g. an alkaline metal hydroxide) in a solvent (e.g. acetone) at room temperatures or with heating. The above-mentioned compound of formula I exhibits an depression effect on contraction of the urinary bladder and is useful for improving arrhythmia, congestive heart failure, asthma, Parkinson disease, angina pectoris, etc. The dosage of the compound of formula I is 0.01 to 20mg/ kg/day in the case of intravenous administration, 0.1 to 20mg/kg/day in the case of intramuscular injection or 0.5 to 100mg/kg/day in the case of oral administration.
Steatotic liver diseases (SLD) are the principal worldwide cause of cirrhosis and end-stage liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic dysfunction-associated alcoholic liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), resulting in asymptomatic liver steatosis, fibrosis, cirrhosis and associated complications. The immune processes include gut dysbiosis, adiposeliver organ crosstalk, hepatocyte death and immune cell-mediated inflammatory processes. Notably, various immune cells such as B cells, plasma cells, dendritic cells, conventional CD4+ and CD8+ T cells, innate-like T cells, platelets, neutrophils and macrophages play vital roles in the development of MetALD and MASLD. Immunological modulations targeting hepatocyte death, inflammatory reactions and gut microbiome include N-acetylcysteine, selonsertib, F-652, prednisone, pentoxifylline, anakinra, JKB-121, HA35, obeticholic acid, probiotics, prebiotics, antibiotics and fecal microbiota transplantation. Understanding the immunological mechanisms underlying SLD is crucial for advancing clinical therapeutic strategies.
Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.
The immune system requires a high energy expenditure to resist pathogen invasion. Macrophages undergo metabolic reprogramming to meet these energy requirements and immunologic activity and polarize to M1-type macrophages. Understanding the metabolic pathway switching in large yellow croaker (Larimichthys crocea) macrophages in response to lipopolysaccharide (LPS) stimulation and whether this switching affects immunity is helpful in explaining the stronger immunity of hypoxia-tolerant L. crocea. In this study, transcript levels of glycolytic pathway genes (Glut1 and Pdk1), mRNA levels or enzyme activities of glycolytic enzymes [hexokinase (HK), phosphofructokinase (PFK), pyruvate kinase (PK), and lactate dehydrogenase A (LDHA)], aerobic respiratory enzymes [pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (IDH), and succinate dehydrogenase (SDH)], metabolites [lactic acid (LA) and adenosine triphosphate (ATP)], levels of bactericidal products [reactive oxygen species (ROS) and nitric oxide (NO)], and transcripts and level changes of inflammatory factors [IL1β, TNFα, and interferon (IFN) γ] were detected in LPS-stimulated L. crocea head kidney macrophages. We showed that glycolysis was significantly induced, the tricarboxylic acid (TCA) cycle was inhibited, and metabolic reprogramming occurred, showing the Warburg effect when immune cells were activated. To determine the potential regulatory mechanism behind these changes, LcHIF-1α was detected and found to be significantly induced and transferred to the nucleus after LPS stimulation. LcHif-1α interference led to a significant reduction in glycolytic pathway gene transcript expression, enzyme activity, metabolites, bactericidal substances, and inflammatory factor levels; a significant increase in the aerobic respiration enzymes; and decreased migration, invasion, and phagocytosis. Further ultrastructural observation by electron microscopy showed that fewer microspheres contained phagocytes and that more cells were damaged after LcHif-1α interference. LcHif-1α overexpression L. crocea head kidney macrophages showed the opposite trend, and promoter activities of Ldha and Il1β were significantly enhanced after LcHif-1α overexpression in HEK293T cells. Our data showed that LcHIF-1α acted as a metabolic switch in L. crocea macrophages and was important in polarization. Hypoxia-tolerant L. crocea head kidney showed a stronger Warburg effect and inhibited the TCA cycle, higher metabolites, and bactericidal substance levels. These results collectively revealed that LcHif-1α may promote the functional activities of head kidney macrophages in protecting hypoxia-tolerant L. crocea from Aeromonas hydrophila infection.
BACKGROUND: Snoezelen is often used for people with profound intellectual and multiple disabilities, but scarcely evaluated. This study aimed to provide insight into the application and perceived effects of snoezelen from the perspective of support persons.
METHOD: We conducted an international survey with professionals (n = 130) and relatives (n = 8) supporting people with profound intellectual and multiple disabilities. Information regarding the application and perceived effects was gathered. Content and descriptive analysis were used.
RESULTS: Despite variation, common characteristics were identified regarding purpose, approach and context. Perceived positive effects mostly concerned improved mental health of the person receiving snoezelen (n = 88). A person-centred approach was reported as important element for positive effects.
CONCLUSIONS: This study describes the use of snoezelen for people with profound intellectual and multiple disabilities. These insights can be used for future research into working elements and effects of snoezelen and facilitate evidence-based support.
This document describes a data processing system for processing a feature vector that comprises features (one or more) that are indicative of dyslexic behavior that are indicative of dyslexic behavior. The data processing system includes a feature classification engine that generates classification metrics for a feature vector. Machine learning logic is used to determine a classification metric for each feature. Features that have a classification metric below a pre-determined threshold are removed. The data processing system includes a prediction engine that generates a prediction value indicative of a predicted likelihood of dyslexia. The prediction engine assigns, to each remaining feature, based on the classification metric of the respective remaining feature, a prediction weight and determines the prediction value based on the prediction weights.
PURPOSE: To obtain the subject agent containing hirudin or its derivative as an active component, effective for suppressing the injury of brain tissue or the development of a vimentin-positive macroglia accompanying to brain injury and extremely effective for the treatment of the injury of central nerve, the injury of brain tissue caused by inflammation, etc. CONSTITUTION: Hirudin or its derivative is used as an active component of the subject agent. The hirudin derivative is e.g. the one expressed by the formula and produced by gene-recombination. The daily administration dose of hirudin or its derivative is usually 0.001-5mg for male adult. It is administered generally by intravenous drip or topical injection. The agent is dissolved in water for injection by using 1 vial of freeze-dried product containing 50mg of hirudin and a proper amount of mannitol in 1 vial or compounded to a carrier, an excipient, a stabilizer, etc.